AbbVie Joins BCMA Race with Tenebio in a US$90 M Upfront Deal
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 2 (Table of Contents)
Published: 14 Feb-2019
DOI: 10.3833/pdr.v2019.i2.2406 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In its first venture into the B-cell maturation antigen (BCMA) space, AbbVie has entered into a global agreement with Teneobio and its affiliate, TeneoOne, to develop and commercialise TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS